Gene Security Network And Ferring Pharmaceuticals Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology

REDWOOD CITY, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Gene Security Network (GSN) and Ferring Pharmaceuticals announced that they have signed an agreement to conduct a clinical trial of GSN’s advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™. The 11-center U.S. trial is designed to evaluate if GSN’s PGD technology helps increase in vitro fertilization (IVF) success rates when using single cell embryo testing for an abnormal number of chromosomes, a condition called aneuploidy. GSN’s Parental Support technology is designed to help improve embryo selection during IVF procedures in order to increase the pregnancy rate following embryo transfer compared with IVF procedures without embryo PGD testing.